Together with a multidisciplinary team of public and private partners spanning animal and human health, Abera announces the start of Bac Vactory on May 31, 2017.
Bac Vactory is a programme that conducts research for the development of bacterial vaccines, with a focus on similar diseases that occur in both humans and animals. By examining bacteria that are closely related and that cause infectious diseases in humans and animals, new, safe and efficient vaccines are to be developed. Combining knowledge of human and veterinary medicine will allow for an integrated ‘One Health’ approach. The use of vaccines represents a cost-effective strategy to address the emerging global human and animal health problems, and offers new ways to minimize the need for antibiotic treatment.
A 2.1 million EUROs subsidy for the Bac Vactory initiative has been awarded by the Dutch NWO-TTW foundation.
The Bac Vactory consortium consists of leading science and business partners: Abera Bioscience, GlaxoSmithKline (GSK), Pulike Bilogical Engineering Inc, Zoetis, Immuno Valley, Utrecht University, Eindhoven University of Technology, Radboud University Medical Centre, Vrije Universiteit Amsterdam, VU medical center and Wageningen Bioveterinary Research.